论文部分内容阅读
淋巴因子激活的杀伤细胞(ALK细胞)是近年来发现的又一类重要的免疫活性细胞,大量文献报道显示联合应用LAK细胞和重组人白细胞介素-2(γIL-2)治疗恶性肿瘤取得明显疗效。自1993年10月以来,我们采用体外液相两步高效活化扩增技术制备的LAK细胞联合γIL-2治疗20例恶性肿瘤患者,取得一定疗效,报告如下:
Lymphokine-activated killer cells (ALK cells) are another important class of immunocompetent cells discovered in recent years. A large number of reports have shown that the use of LAK cells in combination with recombinant human interleukin-2 (γIL-2) to treat malignant tumors is obvious. Efficacy. Since October 1993, we have used LAK cells combined with γIL-2 prepared by two-step high-activity activation amplification in vitro to treat 20 patients with malignant tumors and achieved certain curative effects. The report is as follows: